TCG Crossover Management LLC Buys Shares of 13,135,260 RAPT Therapeutics, Inc. (NASDAQ:RAPT)

TCG Crossover Management LLC purchased a new position in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 13,135,260 shares of the company's stock, valued at approximately $19,751,000. RAPT Therapeutics makes up 1.9% of TCG Crossover Management LLC's portfolio, making the stock its 24th biggest holding. TCG Crossover Management LLC owned about 37.57% of RAPT Therapeutics as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Picton Mahoney Asset Management lifted its stake in RAPT Therapeutics by 994.4% during the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after purchasing an additional 14,697 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock valued at $34,000 after acquiring an additional 25,130 shares during the last quarter. Sei Investments Co. bought a new stake in shares of RAPT Therapeutics during the 4th quarter worth $64,000. Barclays PLC grew its holdings in shares of RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company's stock worth $79,000 after acquiring an additional 29,195 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in RAPT Therapeutics by 401.9% during the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock worth $84,000 after buying an additional 42,636 shares during the period. Institutional investors own 99.09% of the company's stock.

RAPT Therapeutics Price Performance

NASDAQ:RAPT traded up $0.05 during mid-day trading on Friday, reaching $0.97. The stock had a trading volume of 904,905 shares, compared to its average volume of 1,282,622. The business's 50 day moving average is $1.06 and its 200 day moving average is $1.28. RAPT Therapeutics, Inc. has a fifty-two week low of $0.75 and a fifty-two week high of $8.44. The stock has a market cap of $127.62 million, a P/E ratio of -0.35 and a beta of -0.04.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.69). Equities analysts expect that RAPT Therapeutics, Inc. will post -2.14 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of RAPT Therapeutics in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $4.00.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.